MutaMap™ Mutational Activity Map ProStorm® Cytokine Release Assay ProT2® MHC Class II Tetramers: Detecting Antigen-specific CD4+ T cells ProScern®: DC-T Cell Proliferation Assay ProMap®: Naïve T Cell Proliferation Assay ProSentium™: The T cell Immuno-Epiproteome at your fingertips ProImmune REVEAL and ProVE® Pro5® MHC Pentamers HLA Tissue Typing ProPresent® – ProImmune’s Antigen Presentation Assay The Finance of Immunogenicity
MutaMap™ Mutational Activity Map
Back to top
ProStorm® Cytokine Release Assay
ProT2® MHC Class II Tetramers: Detecting Antigen-specific CD4+ T cells
ProScern®: DC-T Cell Proliferation Assay
ProMap®: Naïve T Cell Proliferation Assay
ProSentium™: The T cell Immuno-Epiproteome at your fingertips
ProImmune REVEAL and ProVE®
Dr Jeremy Fry provides a summary of ProImmune’s REVEAL and ProVE® service, the rapid epitope discovery system.
Pro5® MHC Pentamers
Dr Andrew Waller provides an overview of the Pro5 Pentamer technology and the benefits of using MHC pentamers to detect specific CD8 T Cell populations in your research.
HLA Tissue Typing
Dr Briana Betz explains the importance of understanding the HLA types of your study cohort, and how ProImmune can help you.
ProPresent® – ProImmune’s Antigen Presentation Assay
Dr Nikolai Schwabe introduces the ProPresent antigen presentation assay and some of its applications in the field of immunogenicity.
The Finance of Immunogenicity
Managing immunogenicity risk should be a core focus in drug development. ProImmune’s CEO Nik Schwabe explains why.
